NEWS

ReCode Therapeutics Presents New Preclinical Data from mRNA-based Program for Cystic Fibrosis at the ATS 2022 International Conference

MAY 18, 2022

ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic Program in Primary Ciliary Dyskinesia (PCD) in Three Posters at the ATS 2022 International Conference

MAY 15, 2022

ReCode Therapeutics to Present at 2022 RBC Capital Markets Global Healthcare Conference

MAY 10, 2022

RECODE THERAPEUTICS TO PRESENT PRECLINICAL DATA USING PROPRIETARY SORT LNP DELIVERY PLATFORM FROM ITS MRNA-BASED THERAPEUTIC PROGRAMS AT THE ATS 2022 INTERNATIONAL CONFERENCE IN SAN FRANCISCO

MAY 3, 2022

RECODE THERAPEUTICS TO PRESENT AT OPPENHEIMER 32ND ANNUAL HEALTHCARE CONFERENCE

March 9, 2022

RECODE THERAPEUTICS TO PRESENT AT 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

January 10, 2022

RECODE THERAPEUTICS APPOINTS SHEHNAAZ SULIMAN, M.D., MBA, M.PHIL., AS CHIEF EXECUTIVE OFFICER

January 10, 2022

RECODE THERAPEUTICS TO PARTICIPATE IN UPCOMING NOVEMBER INVESTOR CONFERENCES

November 08, 2021

RECODE THERAPEUTICS PRESENTS PRECLINICAL DATA FROM MRNA-BASED CYSTIC FIBROSIS PROGRAM AT 2021 NORTH AMERICAN CYSTIC FIBROSIS CONFERENCE

November 03, 2021

RECODE THERAPEUTICS RAISES OVERSUBSCRIBED SERIES B FINANCING
ROUND OF $80 MILLION

October 21, 2021

RECODE THERAPEUTICS TO PRESENT PRECLINICAL DATA FROM MRNA-BASED PROGRAM FOR CYSTIC FIBROSIS AT UPCOMING VIRTUAL 2021 NORTH AMERICAN CYSTIC FIBROSIS CONFERENCE

October 19, 2021

RECODE THERAPEUTICS ANNOUNCES PARTICIPATION IN UPCOMING OCTOBER INVESTOR CONFERENCES

September 28, 2021

RECODE THERAPEUTICS APPOINTS NICHOLAS P. FRANCE, M.D., AS SENIOR VICE PRESIDENT OF CLINICAL DEVELOPMENT

September 27, 2021

RECODE THERAPEUTICS ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR CONFERENCES

September 3, 2021

RECODE THERAPEUTICS APPOINTS ANGÈLE MAKI, PH.D., AS SENIOR VICE PRESIDENT OF BUSINESS DEVELOPMENT

August 16, 2021

RECODE THERAPEUTICS PRESENTS ENCOURAGING PRECLINICAL DATA FROM INHALED MRNA THERAPEUTICS PROGRAM IN PRIMARY CILIARY DYSKINESIA AT THE 2021 PCD ON THE MOVE VIRTUAL SCIENTIFIC CONFERENCE

August 5, 2021

RECODE THERAPEUTICS TO PARTICIPATE IN UPCOMING AUGUST INVESTOR CONFERENCES

August 3, 2021

RECODE THERAPEUTICS TO PRESENT PRECLINICAL DATA FROM MRNA-BASED PROGRAM FOR PRIMARY CILIARY DYSKINESIA AT THE 2021 PCD ON THE MOVE VIRTUAL SCIENTIFIC CONFERENCE

July 30, 2021

RECODE THERAPEUTICS TO PRESENT AT WILLIAM BLAIR BIOTECH FOCUS CONFERENCE 2021

July 08, 2021

RECODE THERAPEUTICS TO PARTICIPATE IN UPCOMING JUNE INVESTOR CONFERENCES

June 14, 2021

RECODE THERAPEUTICS PRESENTS PRECLINICAL DATA USING SORT-LNP^TM AND RNA PLATFORMS TO RESCUE CFTR FUNCTION AT THE 44TH EUROPEAN CYSTIC FIBROSIS CONFERENCE (ECFS)

June 11, 2021

RECODE THERAPEUTICS TO PRESENT PRECLINICAL DATA USING SORT-LNP^TM AND RNA PLATFORMS TO RESCUE CFTR FUNCTION AT THE 44TH EUROPEAN CYSTIC FIBROSIS CONFERENCE (ECFS)

May 24, 2021

RECODE THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

February 16, 2021

RECODE THERAPEUTICS TO PRESENT AT 39th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

January 11, 2021

RECODE THERAPEUTICS APPOINTS JULIE EASTLAND AS CHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER

October 13, 2020

RECODE THERAPEUTICS STRENGTHENS LEADERSHIP TEAM WITH NEW APPOINTMENTS

September 9, 2020

RECODE THERAPEUTICS RAISES $80 MILLION IN OVERSUBSCRIBED SERIES A FINANCING

March 26, 2020